In this free webinar, learn about the current landscape, latest advancements and common challenges of novel glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic, obesity and metabolic disease trials. Topics will also include strategies for navigating the increasing competition for suitable patient enrollment and the importance of continued mitigation of early withdrawals due to gastrointestinal (GI) side effects.
TORONTO, Oct. 12, 2023 /PRNewswire-PRWeb/ -- Join us for a comprehensive webinar delving into the latest advancements in novel glucagon-like peptide-1 (GLP-1) receptor agonists in diabetic, obesity and metabolic disease trials. Nearly 20 years after the approval of Exenatide as the first glucagon-like peptide-1 receptor agonist (GLP-1RA) for the treatment of Type 2 Diabetes, the results of recent clinical trials have driven a resurgence in interest in their clinical and off-label use in both diabetic and non-diabetic obese populations.
Novel GLP-1/glucose-dependent insulinotropic polypeptide (GIP) and triple-acting GLP/GIP/glucagon (GCG) receptor agonists show higher potency than existing GLP-1RAs, and new oral formulations and longer dosing schedules are further driving expansion within this class of therapy.
At the same time, the outcomes of these programs are broadening. Comorbid steatotic liver disease endpoints are becoming increasingly important in obesity trials — the role of GLP-1s (including dual and triple agonists) as primary or co-therapy for nonalcoholic steatohepatitis (NASH) is creating an increasing need for effective pre-screening strategies to pre-identify potential participants. Further, recent data has shown a decrease in cardiovascular risk in obese, non-diabetic patients treated with Semaglutide.
In this webinar, the featured speakers will discuss how the successful development of GLP-1 agonists in this rapidly evolving clinical landscape will require the historical lessons learned in the management of patients on these drugs to be applied in these new therapeutic populations, and the specific medical and operational challenges presented in clinical trial delivery, including but not limited to:
- The importance of continuing to ensure the mitigation of early withdrawals due to gastrointestinal (GI) side effects
- Strategies to pre-identify and enroll targeted patients while navigating the increasing competition for suitable patients in these new populations
- The challenge of ensuring patient access and diversity
Panelists will share their insights and recommended strategies gleaned from 25+ years of clinical and research experience in diabetes and metabolic disease to better equip the attendees to meet the future demands for the successful conduct of GLP-1 studies in today's rapidly evolving clinical landscape.
Join the following experts from the PPD clinical research business of Thermo Fisher Scientific: Graham Ellis, MD, Executive Director, Medical Science and Strategy; Vijay Shivaswamy, Medical Director, Pharmacovigilance; and Eling Gaines, Oversight Director, Cardiovascular, Metabolic and Critical Care, for the live webinar on Monday, October 30, 2023, at 11am EDT (4pm CET/EU-Central).
For more information, or to register for this event, visit The Evolution of GLP-1s: Overcoming Clinical Development Challenges.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article